Fujifilm and Predictive Oncology Announce Collaboration to Reduce Protein Interference in Bacterial Endotoxin Detection Testing of Biopharmaceuticals
Retrieved on:
Thursday, April 25, 2024
Corporation (Fujifilm), a supplier of high purity chemicals and reagents, and Predictive Oncology Inc., (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that the companies have entered into a collaboration and co-marketing agreement to reduce protein interference in bacterial endotoxin testing of biopharmaceutical products.
Key Points:
- Corporation (Fujifilm), a supplier of high purity chemicals and reagents, and Predictive Oncology Inc., (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that the companies have entered into a collaboration and co-marketing agreement to reduce protein interference in bacterial endotoxin testing of biopharmaceutical products.
- Per the terms of the agreement, Predictive Oncology will utilize its novel EndoPrep™ sample treatment technology (EndoPrep), together with Fujifilm’s PYROSTAR™ bacterial endotoxin detection reagent (PYROSTAR), to detect residual endotoxins more accurately in biopharmaceuticals by eliminating protein interference from the drug product in the detection assay.
- The Limulus Amebocyte Lysate (LAL) test is recognized by the U.S. Pharmacopeia (USP) for determining endotoxin levels in many biopharmaceuticals.
- *Compared to traditional industry standards of utilizing heat-treatment or dilution to remove the interference of high protein.